(VIANEWS) – On Friday, NeuroMetrix (NASDAQ: NURO) shares experienced an 18.19% drop over five sessions, falling from EUR0.64 to EUR0.53 as of 19:00 EST. This drop follows on the back of its recent downward trend; although overall NASDAQ rose 0.38% reaching EUR12,643.11, NeuroMetrix performance remains dismal; their last closing price at EUR0.54 represents 75.23% below their 52-week high of EUR2.18.
About NeuroMetrix
NeuroMetrix, a commercial-stage neurotechnology company, designs, develops, and markets medical devices for diagnostic and therapeutic applications of nerve response analysis. Their primary products are DPNCheck, Quell and the ADVANCE system which are utilized by managed care organizations, primary care physicians, pain medicine specialists as well as other medical professionals. Established in 1996 and located in Woburn Massachusetts –
Yearly Analysis
According to available data, NeuroMetrix stock is currently trading at EUR0.53, below its 52-week low of EUR0.60. Furthermore, their EBITDA stands at EUR7.12.
Given this data, it is key to note that the stock’s current value is lower than its 52-week low – suggesting the market views the company’s financial performance as subpar – though an EBITDA figure of EUR7.12 indicates they still generate profits and could provide an asset class investment opportunity for investors.
Overall, investors should proceed with caution when considering NeuroMetrix investments as the stock is trading below its 52-week low and could signal potential financial trouble for the company. On the plus side, its positive EBITDA could provide investors with some hope – it may be wiser to conduct further research and analysis before making their final decision about investing.
Technical Analysis
NeuroMetrix’s stock price has experienced a substantial drop, falling well below both its 50-day and 200-day moving averages. Furthermore, volume has significantly exceeded average trading activity indicating increased trading activity. Furthermore, volatility has been relatively high, with an average intraday variation over the last week being 2.32%; 0.544% over one month; and 3.40 % over three quarters.
Stochastic oscillator, a widely-used technical indicator that compares a stock’s closing price to its price range over a given time period, shows NeuroMetrix is oversold (=20). This may indicate undervaluation and could signal potential opportunities for price recovery in NeuroMetrix shares.
Given these circumstances, investors may wish to closely observe NeuroMetrix stock over the coming days and weeks in order to observe whether it stabilizes or resumes its downward trajectory. Furthermore, long-term investments may also be worth exploring due to NeuroMetrix’s oversold condition and potential growth potential.
Quarter Analysis
Based on this information, year-on-year quarterly revenue growth for this stock has seen a decline of 22.6% year over year resulting in current twelve month revenue of 7.2M for investors to consider as this indicates its revenue is not increasing as fast. This could signal to potential buyers that growth of revenue for this company has become less rapid over time than anticipated by previous investors.
Before making investment decisions, investors should carefully evaluate a company’s profitability, competitive landscape and overall market trends. Furthermore, investors should review both income statement and balance sheet to gain a clear understanding of its financial health as well as any opportunities for future expansion.
Equity Analysis
NeuroMetrix’s financial information shows a negative trailing twelve month earnings per share of EUR-0.72, signalling to shareholders that it has failed to generate any profits over the last year. Furthermore, its return on equity (ROE) for that same period was negative at -24.14%, signifying no profits to shareowners relative to equity investments made into NeuroMetrix by them.
Given all this information, it may be difficult for investors to have confidence in a company’s ability to generate positive returns on their investments. But past performance does not always portend future success and so investors should also carefully consider other factors, including growth prospects, competitive position and market conditions before making any decisions regarding investments. Furthermore, reviewing financial statements as well as consulting a financial professional might prove beneficial before making a final decision about investments.
More news about NeuroMetrix (NURO).
